Sadot Group Inc. (SDOT): Nasdaq/NYSE listing notice — Nasdaq notifies Muscle Maker of bid-price non-compliance; hearing requested

Sadot Group Inc.

Received Nasdaq letter on Jan 31, 2023 for failing to maintain $1.00 minimum bid price per Nasdaq Listing Rule 5550(a)(2).
Company will request a hearing by Feb 7, 2023; hearing stays any further delisting action pending Panel decision.
Previously granted 180-day extensions to regain compliance expired Jan 30, 2023; company now in its second extension period.
No assurance the Panel will grant continued listing or an additional extension.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Sadot Group Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 31, 2023, Muscle Maker, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the Company’s non-compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) as of January 31, 2023, the Company would need to request a hearing to appeal the determination. The Company will be requesting a hearing before a Nasdaq Hearings Panel (the

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Sadot Group Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-003523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.